Michigan, and 13 addition municipalities that send wastewater to the Wayne's Treatment Plant (the ''Plant''). The case was resolved in 1994 by a Consent Decree pursuant to which defendants agreed to attain and maintain compliance with the Plant's National Pollutant Discharge Elimination System permit limits and to comply with Decree-mandated interim limits during construction of Plant and collection-system improvements. Defendants further agreed to complete capital improvements needed at the Plant and in its collection system. The capital-improvements project, detailed in a 1993 Project Plan incorporated by reference in the 1994 Decree, included steps to achieve: the removal of improper infiltration-and-inflow; the improvement of transport and storage capacity in the Plant's wastewater collection system by constructing retention-equalization basins and an underground tunnel for storage and transport of untreated wastewater; and the upgrade the Plant's facilities to ensure that all flows meet Permit-mandated limits.

Since entry of the Consent Decree in 1994, defendants have submitted studies, plans, and design documents required by the 1994 Consent Decree to the U.S. Environmental Protection Agency and the Michigan Department of Environmental Quality. These documents contain recommendations for changes in the design of certain components of the work required by the 1994 Consent Decree, including: the modification of the wastewater storage and transport tunnel required by the original decree; further improvements in Plant treatment capacity; further study and design work prior to commencement of construction of a detention basin required by the 1994 Decree, referred to as the Eureka Basin, intended to eliminate sewer overflows and backups in the Plant's collection system above the proposed basin; and construction of a new connecting conduit, rather than a new Plant outfall, that would convey excess flows from the Plant to another treatment plant for treatment and discharge. The Amendment, if approved by the Court, would modify the injunctive relief provisions of the 1994 Decree to reflect these changes to the 1993 Project Plan. In all other respects, the 1994 Decree would remain the same.

The Department of Justice will receive for a period of thirty (30) days from the date of this publication comments relating to the Amendment. Comments should be addressed to the Assistant Attorney General of the Environment and Natural Resources Division, Department of Justice, Washington, DC 20530, and should refer to *United States and State of Michigan* v. *Wayne County et al.*, D.J. Ref. 90–5–1–1–2766.

The Amendment may be examined at the Office of the United States Attorney, Eastern District of Michigan, 211 W. Fort Street, Suite 2300, Detroit, MI 48226, at U.S. EPA Region 5, 77 West Jackson Blvd., Chicago, Illinois, 60604, and at the Consent Decree Library, 1120 G Street, NW., 4th Floor, Washington, DC 20005, (202) 624–0892. A copy of the Amendment may be obtained in person or by mail from the Consent Decree Library, 1120 G Street, NW., 4th Floor, Washington, DC 20005. In requesting a copy, please enclose a check in the amount of $8.50 (25 cents per page reproduction cost) payable to the Consent Decree Library.

Joel M. Gross,

Chief, Environmental Enforcement Section, Environment and Natural Resources Division.

[FR Doc. 97–30588 Filed 11–20–97; 8:45 am]

BILLING CODE 4410–15–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[DEA #167F]

Controlled Substances: Established Initial Aggregate Production Quotas for 1998

AGENCY: Drug Enforcement Administration (DEA), Justice.

ACTION: Notice of aggregate production quotas for 1998.

SUMMARY: This notice establishes initial 1998 aggregate production quotas for controlled substances in Schedules I and II of the Controlled Substances Act.

EFFECTIVE DATE: November 21, 1997.

FOR FURTHER INFORMATION CONTACT: Frank L. Sapienza, Chief, Drug & Chemical Evaluation Section, Drug Enforcement Administration, Washington, DC 20537, Telephone: (202) 307–7183.

SUPPLEMENTARY INFORMATION: Section 306 of the Controlled Substances Act (21 U.S.C. 826) requires that the Attorney General establish aggregate production quotas for each basic class of controlled substance listed in Schedules I and II. This responsibility has been delegated to the Administrator of the DEA by Section 0.100 of Title 28 of the Code of Federal Regulations. The Administrator, in turn, has redelegated this function to the Deputy Administrator pursuant to Section 0.104 of Title 28 of the Code of Federal Regulations.

On September 2, 1997, a notice of the proposed initial 1998 aggregate production quotas for certain controlled substances in Schedules I and II was published in the **Federal Register** (62 FR 46373). All interested persons were invited to comment on or object to these proposed aggregate production quotas on or before October 2, 1997.

One company commented that the initial 1998 aggregate production quota for amphetamine is insufficient to provide for the estimated medical, scientific, research and industrial needs of the United States, for export requirements and for the establishment and maintenance of reserve stocks.

Another company commented that the initial 1998 aggregate production quotas for codeine (for sale), diphenoxylate, morphine (for sale), opium, and oxycodone (for sale) are insufficient to provide for the estimated medical, scientific, research and industrial needs of the United States, for export requirements and for the establishment and maintenance of reserve stocks.

After a review of 1997 manufacturing quotas, current 1997 sales and inventories, 1998 export requirements and research and product development requirements, the DEA agrees that increases are necessary for amphetamine, codeine (for sale), morphine (for sale) and oxycodone (for sale). Regarding diphenoxylate and opium, the DEA has determined that the proposed initial 1998 aggregate production quotas are sufficient to meet the 1998 estimated medical, scientific, research and industrial needs of the United States.

The Office of Management and Budget has determined that notices of aggregate production quotas are not subject to centralized review under Executive Order 12866. This action has been analyzed in accordance with the principles and criteria contained in Executive Order 12612, and it has been determined that this matter does not have sufficient federalism implications to warrant the preparation of a Federalism Assessment.

The Acting Deputy Administrator hereby certifies that this action will have no significant impact upon small entities whose interests must be considered under the Regulatory Flexibility Act, 5 U.S.C. 601 *et seq.* The establishment of aggregate production quotas for Schedules I and II controlled substances is mandated by law and by international treaty obligations. Aggregate production quotas apply to approximately 200 DEA registered bulk and dosage from manufacturers of Schedules I and II controlled

substances. The quotas are necessary to provide for the estimated medical, scientific, research and industrial needs of the United States, for export requirements and the establishment and maintenance of reserve stocks. While aggregate production quotas are of primary importance to large manufacturers, their impact upon small entities is neither negative nor beneficial. Accordingly, the Acting Deputy Administrator has determined that this action does not require a regulatory flexibility analysis.

Therefore, under the authority vested in the Attorney General by Section 306 of the Controlled Substances Act of 1970 (21 U.S.C. 826), delegated to the Administrator of the DEA by Section 0.100 of Title 28 of the Code of Federal Regulations, and redelegated to the Deputy Administrator pursuant to Section 0.104 of Title 28 of the Code of Federal Regulations, the Acting Deputy Administrator hereby orders that the 1998 initial aggregate production quotas for the following controlled substances, expressed in grams of anhydrous acid or base, be established as follows:

Basic class	Established initial 1998 quotas
Schedule I:	
2,5-Dimethoxyamphetamine	15,000,100
2,5-Dimethoxy-4-ethylamphetamine (DOET)	2
3-Methylfentanyl	14
3-Methylthiofentanyl	2
3,4-Methylenedioxyamphetamine (MDA)	25
3,4-Methylenedioxy-N-ethylamphetamine (MDEA)	30
3,4-Methylenedioxymethamphetamine (MDMA)	20
3,4,5-Trimethoxyamphetamine	2
4-Bromo-2,5,-Dimeththoxyamphetamine	2
4-Bromo-2,5-Dimeththoxyphenethylamine (2–CB)	2
4-Methoxyamphetamine	100,100
4-Methylaminorex	2
4-Methyl-2,5-Dimethoxyamphetamine (DOM)	2
5-Methoxy-3,4-Methylenedioxyamphetamine	2
Acetyl-alpha-methylfentanyl	2
Acetylmethadol	7
Allylprodine	2
Alpha-acetylmethadol	7
Alpha-ethyltryptamine	2
Alphameprodine	2
Alpha-methadol	2
Alpha-methylfentanyl	2
Alphaprodine	2
Alpha-methylthiofentanyl	2
Aminorex	7
Beta-acetylmethadol	2
Beta-hydroxyfentanyl	2
Beta-hydroxy-3-methylfentanyl	2
Beta-methadol	2
Betaprodine	2
Bufotenine	2
Cathinone	9
Codeine-N-oxide	2
Diethyltryptamine	2
Difenoxin	16,000
Dihydromorphine	7
Dimethyltryptamine	2
Ethylamine Analog of PCP	5
Heroin	2
Hydroxypethidine	2
Lysergic acid diethylamide (LSD)	57
Mescaline	7
Methaqualone	17
Methcathinone	11
Morphine-N-oxide	2
N-Ethylamphetamine	7
N-Hydroxy-3,4-Methylenedioxyamphetamine	4
N,N-Dimethylamphetamine	7
Noracymethadol	2
Norlevorphanol	2
Normethadone	7
Normorphine	7
Para-fluorofentanyl	2
Pholcodine	2
Psilocin	2
Psilocybin	2
Tetrahydrocannabinols	26,000
Thiofentanyl	2
Trimeperidine	2

Basic class	Established initial 1998 quotas
Schedule II:	
1-Phenylcyclohexylamine	15
1-Piperidinocyclohexanecarbonitrile (PCC)	12
Alfentanil	8,100
Amobarbital	12
Amphetamine	4,037,000
Cocaine	550,100
Codeine (for sale)	62,020,000
Codeine (for conversion)	18,460,000
Desoxyephedrine	1,332,000
1,300,000 grams of levodesoxyephedrine for use in a non-controlled, non-prescription product and 32,000 grams for methamphetamine.	
Dextropropoxyphene	109,500,000
Dihydrocodeine	189,000
Diphenoxylate	1,600,000
Ecgonine	651,000
Ethylmorphine	12
Fentanyl	202,000
Glutethimide	2
Hydrocodone (for sale)	13,908,000
Hydrocodone (for conversion)	3,000,000
Hydromorphone	766,000
Isomethadone	12
Levo-alpha-acetylmethadol (LAAM)	356,000
Levomethorphan	2
Levorphanol	15,000
Meperidine	9,311,000
Methadone (for sale)	3,790,000
Methadone (for conversion)	1,169,000
Methadone Intermediate	6,777,000
Methamphetamine (for conversion)	723,000
Methylphenidate	14,442,000
Morphine (for sale)	11,535,000
Morphine (for conversion)	75,918,000
Nabilone	2
Noroxymorphone (for sale)	25,000
Noroxymorphone (for conversion)	2,117,000
Opium	615,000
Oxycodone (for sale)	9,032,000
Oxymorphone	120,000
Pentobarbital	16,562,000
Phencyclidine	60
Phenmetrazine	2
Phenylacetone	10
Secobarbital	301,000
Sufentanil	700
Thebaine	9,580,000

Dated: November 17, 1997.

James S. Milford,

Acting Deputy Administrator.

[FR Doc. 97–30651 Filed 11–20–97; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Federal Bureau of Investigation

Criminal Justice Information Services; Agency Information Collection Activities; Proposed Collection; Comment Request

ACTION: Notice of information collection under review: Supplementary homicide report.

The proposed information collection is published to obtain comments from the public and affected agencies. Comments are encouraged and will be accepted until January 20, 1998.

Request written comments and suggestions from the public and affected agencies concerning the proposed collection of information. Your comments should address one or more of the following four points:

(1) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

(2) Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

(3) Enhance the quality, utility and clarity of the information to be collected; and

(4) Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses.

Comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time should be directed to SSA Paul J. Gans (phone number and address